Bristol-Myers Squibb Company (BMY)

Return on equity (ROE)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	8,025,000	8,285,000	7,963,000	7,311,000	6,327,000	6,677,000	6,617,000	6,251,000	6,994,000	-5,405,000	-5,079,000	-6,219,000	-9,015,000	-44,000	-563,000	954,000	3,439,000	5,655,000	6,203,000	5,144,000
Total stockholders’ equity	US$ in thousands	29,430,000	28,998,000	31,973,000	31,824,000	31,061,000	32,671,000	32,600,000	31,580,000	35,946,000	37,213,000	36,808,000	37,605,000	37,822,000	50,158,000	49,094,000	49,911,000	51,598,000	17,648,000	16,049,000	15,218,000
ROE		27.27%	28.57%	24.91%	22.97%	20.37%	20.44%	20.30%	19.79%	19.46%	-14.52%	-13.80%	-16.54%	-23.84%	-0.09%	-1.15%	1.91%	6.66%	32.04%	38.65%	33.80%

December 31, 2023 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $8,025,000K ÷ $29,430,000K
= 27.27%

The return on equity (ROE) for Bristol-Myers Squibb Co. has shown a positive trend over the past eight quarters. ROE has been consistently above 20% since Q1 2022, indicating the company's ability to generate strong returns for its shareholders relative to their equity investment.

The upward trajectory of ROE from Q1 2022 to Q4 2023 suggests that Bristol-Myers Squibb Co. has been effectively utilizing its shareholders' equity to generate profit. This improving trend reflects positively on the company's management efficiency and profitability.

The latest ROE of 27.27% in Q4 2023 demonstrates a notable increase from the previous quarter, indicating enhanced profitability and efficiency in generating returns for shareholders. Overall, Bristol-Myers Squibb Co.'s ROE performance illustrates a strong financial position and effective capital management during the period under review.